Amended Current Report Filing (8-k/a)
14 Décembre 2017 - 8:54PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
Amendment No. 1
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
December
14, 2017
IMMUNE PHARMACEUTICALS, INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
001-36602
|
52-1841431
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
550 Sylvan Avenue, Suite 101, Englewood Cliffs, NJ
|
07632
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including
area code:
(201) 464-2677
(Former name or former address, if changed
since last report) N/A
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
|
¨
|
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
|
¨
|
Item 4.01.
|
Change in Registrant’s Certifying Accountant.
|
On December 13, 2017, Immune Pharmaceuticals, Inc. (the “Company”)
filed a Form 8-K (“the “Initial 8-K”) disclosing that the Audit Committee of the Company notified BDO USA, LLP
("BDO"), it’s independent registered public accounting firm, that the Company had determined to dismiss BDO effective
as of December 7, 2017.
This Form 8-K/A amends Item 4.01 of the Initial Form 8-K and
speaks as of December 14, 2017.
The Company provided BDO with a copy of the Initial 8-K prior
to the Company’s filing of it with the Securities and Exchange Commission (the “SEC”), and at such time requested
that BDO furnish it with a letter addressed to the SEC stating whether BDO agrees with the statements made by the Company in the
Initial 8-K. BDO has since furnished the requested letter, which is filed herewith as Exhibit 16.1 to this Form 8-K/A.
Item 9.01
|
Financial Statements and Exhibits
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
IMMUNE PHARMACEUTICALS INC.
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Elliot M. Maza
|
|
|
Name:
|
Elliot M. Maza
|
|
|
Title:
|
President and Chief Executive Officer
|
|
Date: December 14, 2017
(USOTC:IMNPQ)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
(USOTC:IMNPQ)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about (OTCMarkets): 0 recent articles
Plus d'articles sur Immune Pharmaceuticals Inc